ArticleJournal of radiation research2025
National survey on definitive radiotherapy practices for locally advanced non-small cell lung cancer in Japan: JROSG 23-3.
Article in Journal of radiation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Definitive radiotherapy for non-small-cell lung cancer: current practice and future directions.Japanese journal of radiology · 2026Review
- Definitive radiotherapy practices for small-cell lung cancer in Japan: a national survey (JROSG 23-3).Journal of radiation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This survey was conducted to examine the real-world practice of definitive chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC) in Japan, aiming to standardize treatment, reduce inter-institutional disparities and identify areas for future research. A questionnaire was sent to members of the Japanese Radiation Oncology Study Group through a mailing list, with responses collected between December 15, 2023, and March 14, 2024. Responses from 112 institutions revealed that 81.2% either did not set general upper age limits or established limits at 80 years or older for definitive CRT in LA-NSCLC. The most common absolute contraindications were active interstitial pneumonia (60.7%) and contralateral hilar lymph node metastasis (42.0%). Relative contraindications involved dose-volume indices of the normal lung (70.5%). The most commonly adopted dose-volume indices were lung V20Gy < 30%, lung V5Gy < 60% and mean lung dose <20 Gy, while no definite indices were established for heart V50Gy and mean heart dose in half of the institutions. Additionally, 88.4% of institutions reported using IMRT for LA-NSCLC. Involved-field radiotherapy (IFRT) was adopted regardless of institutional size, and institutions with higher IMRT usage for LA-NSCLC also had higher IFRT adoption rates. In conclusion, this nationwide survey revealed the expanded use of definitive CRT and a growing emphasis on reducing lung dose to mitigate pulmonary toxicities, facilitated by advancements in IMRT and IFRT. Regularly conducting these surveys is essential to monitor evolving treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.